<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004905</url>
  </required_header>
  <id_info>
    <org_study_id>LUMC-5892</org_study_id>
    <secondary_id>NU-L94H2</secondary_id>
    <secondary_id>CDR0000067584</secondary_id>
    <secondary_id>NCI-G00-1702</secondary_id>
    <nct_id>NCT00004905</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia</brief_title>
  <official_title>Pilot Study of Intensive Chemotherapy Followed by Peripheral Blood Stem Cell Harvesting for Autotransplantation of Adults With Chronic Myelogenous Leukemia and High Risk Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to&#xD;
      give higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Clinical trial to study the effectiveness of combination chemotherapy plus&#xD;
      peripheral stem cell transplantation in treating patients who have chronic myelogenous&#xD;
      leukemia or acute leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine safety and toxicity of induction and transplant regimens in patients&#xD;
      with chronic myelogenous leukemia or high-risk acute leukemia. II. Determine efficacy of&#xD;
      collecting peripheral blood stem cells (PBSC) during early hematopoietic recovery from&#xD;
      intensive chemotherapy as a means for in vivo enrichment for cytogenetically normal&#xD;
      progenitor cells in this patient population. III. Correlate cytogenetic and molecular&#xD;
      responses in the peripheral blood and bone marrow with clinical response, time to&#xD;
      progression, and survival in these patients at several timepoints before and after&#xD;
      myelosuppressive and myeloablative therapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to disease (chronic&#xD;
      myelogenous leukemia vs acute lymphoblastic leukemia vs acute myelogenous leukemia). Patients&#xD;
      receive cytarabine IV over 4 hours, etoposide IV over 1.5-2 hours, and idarubicin IV over&#xD;
      5-10 minutes on days 1, 3, and 5. Filgrastim (G-CSF) is administered subcutaneously (SC)&#xD;
      daily beginning on day 2 and continuing until blood counts recover. Chronic myelogenous&#xD;
      leukemia: On day 14 following chemotherapy, if bone marrow biopsy shows less than 20%&#xD;
      cellularity and a peripheral blood sample contains greater than 50% cytogenetically normal&#xD;
      cells, patients receive a second induction course followed by apheresis. Patients with less&#xD;
      than 50% cytogenetically normal cells are also considered for a second induction course.&#xD;
      Patients with no response or progressive disease are removed from the study. Acute leukemia:&#xD;
      On day 14 following chemotherapy, if bone marrow biopsy shows less than 20% cellularity and&#xD;
      the peripheral blood sample shows 100% cytogenetically normal cells, patients receive a&#xD;
      second induction course followed by apheresis. Patients with high risk disease in first&#xD;
      remission at time of study entry undergo apheresis during recovery from first course of&#xD;
      induction therapy and second course may be omitted. Patients receive second induction course&#xD;
      followed by G-CSF as after first induction course. Once blood counts recover, patients&#xD;
      undergo harvest of peripheral blood stem cells (PBSC). Patients also undergo bone marrow stem&#xD;
      cell collection in case of failure of PBSC transplantation (PBSCT). Patients receive the&#xD;
      following conditioning regimen: total body irradiation twice a day on days -8 to -5;&#xD;
      etoposide IV over 4 hours on day -4; and cyclophosphamide IV over 2 hours on day -2. PBSCT is&#xD;
      conducted on day 0. G-CSF SC is administered beginning on day 1 and continues until blood&#xD;
      counts recover. Patients receive maintenance therapy with interferon alfa SC 3 times a week&#xD;
      for 12 months. Patients are followed weekly for 3 months and then monthly until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: One of the following hematologic conditions: Chronic phase or&#xD;
        advanced chronic myelogenous leukemia Acute lymphoblastic leukemia: -relapsed -in second&#xD;
        remission or later -in first remission with unfavorable prognostic features Acute&#xD;
        myelogenous leukemia: -in second remission or later -in first remission with high-risk&#xD;
        features Detectable clonal cytogenetic or molecular abnormality at time of diagnosis Not&#xD;
        eligible for allogenic bone marrow transplant&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 to 60 Performance status: Not specified Life expectancy:&#xD;
        Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 2 times upper limit&#xD;
        of normal (ULN) SGOT/SGPT less than 2 times ULN Renal: Creatinine clearance greater than 60&#xD;
        mL/min Cardiovascular: Ejection fraction greater than 45% Pulmonary: DLCO greater than 60%&#xD;
        FEV1 greater than 60% Other: No serious underlying medical condition that would preclude&#xD;
        study Not pregnant or nursing No cerebellar dysfunction&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: Prior&#xD;
        chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: Prior radiotherapy&#xD;
        allowed Surgery: Prior surgery allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane N. Winter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2001</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>September 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2004</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

